UroGen Pharma Ltd
URGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.13B
Close$
$-31.17
169.5% downside
Current Fair Value
169.5% downsideOvervalued by 169.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.13 Billion |
|---|---|
| Enterprise Value | $2.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 1.58 |
| Outstanding Shares | 50,380,112 |
Return
| Return on Equity | 73.75% |
|---|---|
| Return on Assets | -38.65% |
| Return on Invested Capital | -39.34% |
Valuation & Multiples
| P/E Ratio | -22.03 |
|---|---|
| PEG | 30.91 |
| Price to Sales | 14.96 |
| Price to Book Ratio | -14.96 |
| Enterprise Value to Revenue | 11.88 |
| Enterprise Value to EBIT | -29.9 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -1.48 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$63.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$90.58 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7613▲ 60.73% |
|---|---|
| Total Calls | 226,200▼ 83.42% |
| Total Puts | 172,200▼ 18.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.55%▲ 1.70% |
|---|---|
| Total Invested | $835.18M▼ 18.41% |
| Investors Holding | 179▲ 3.00% |
ESG Score
No data
About UroGen Pharma Ltd
CEO: Elizabeth Barrett